Global pharma major Lupin Limited (Lupin) today announced that its Unit-2 manufacturing facility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (U.S. FDA). The inspection was conducted from August 7 to August 11, 2023 and concluded
Collaboration to strengthen healthcare system, reduce prevalence and improve health outcomes for patients diagnosed with Cardiovascular and COPD/Asthma disease in Alwar Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of Lupin Limited (‘Lupin’ BSE: 500257 |NSE: LUPIN | Reuters: LUPIN.BO |Bloomberg:
